Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin



Status:Recruiting
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/5/2019
Start Date:December 12, 2017
End Date:December 31, 2025

Use our guide to learn which trials are right for you!

Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin

This randomized phase II/III trial studies how well radiation therapy works with durvalumab
or cetuximab in treating patients with head and neck cancer that has spread to a local and/or
regional area of the body who cannot take cisplatin. Radiation therapy uses high energy
x-rays to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such
as durvalumab or cetuximab, may help the body's immune system attack the cancer, and may
interfere with the ability of tumor cells to grow and spread. It is not known if radiation
therapy with durvalumab will work better than the usual therapy of radiation therapy with
cetuximab in treating patients with head and neck cancer.

PRIMARY OBJECTIVES:

I. To determine the safety of radiotherapy (RT) with concurrent and adjuvant anti-PD-L1
therapy (MEDI4736 [durvalumab]) is safe in patients with locoregionally advanced head and
neck cancer (HNC) who have a contraindication to cisplatin. (Lead-in) II. To test the
hypothesis that concurrent RT and anti-PD-L1 therapy improves progression free survival (PFS)
compared to standard therapy (RT with concurrent cetuximab) in patients with locoregionally
advanced HNC who have a contraindication to cisplatin. (Phase II) III. To test the hypothesis
that concurrent RT and anti-PD-L1 therapy improves overall survival compared to standard
therapy (RT with concurrent cetuximab) in patients with locoregionally advanced HNC who have
a contraindication to cisplatin. (Phase III)

SECONDARY OBJECTIVES:

I. To compare toxicity using Common Terminology Criteria for Adverse Events (CTCAE) and
Patient Reported Outcomes (PRO)-CTCAE between patients treated with RT + anti-PD-L1 therapy
versus RT/cetuximab.

II. To test the effect of anti-PD-L1 therapy in the subpopulation of patients with tumors
that overexpress PD-L1.

III. To compare overall survival, response (at 4-month fludeoxyglucose F-18 [FDG]-positron
emission tomography [PET]-computed tomography [CT]), locoregional failure, distant
metastasis, and competing mortality in the two arms by known risk factors, including p16
status and omega score.

IV. To test the hypothesis that MEDI4736 (durvalumab) therapy arm will have less decline in
the physical function domain of European Organization for Research and Treatment of Cancer
Core Questionnaire (EORTC QLQ-C30 version 3.0) based on the change in score from baseline to
12 months from end of RT, compared to the cetuximab-RT arm in patients with locoregionally
advanced HNC who have a contraindication to cisplatin.

V. To test the hypothesis that MEDI4736 (durvalumab) therapy arm at 1 year (from end of RT)
will have less decline in swallowing related quality of life (QOL) using the M. D. Anderson
Dysphagia Inventory (MDADI) total composite score, based on the change in score from baseline
to 12 months from end of RT, compared to the cetuximab-RT arm in patients who are medically
unfit for cisplatin.

VI. To compare swallowing related performance and function short and long term using the
Performance Status Scale for Head & Neck Cancer Patients (PSS-HN).

VII. To evaluate gastrostomy tube retention rates between arms.

EXPLORATORY OBJECTIVES:

I. To test the hypothesis that radiation combined with MEDI4736 (durvalumab) enhances the
adaptive immune response using three types of immunophenotyping compared to radiation
combined with cetuximab.

II. To compare overall QOL short term (end RT-8 months) and long term (12-24 months from end
of RT) between arms using the EORTC QLQ-C30 version 3.0/HN35.

III. To evaluate swallowing related QOL short term (end RT-8 months) and long term (12-24
months from end of RT) using the EORTC Head and Neck (HN)35 swallowing domain and MDADI
(subscales) between arms in patients with locoregionally advanced HNC who have a
contraindication to cisplatin.

IV. To evaluate patient reported fatigue using the fatigue items in the EORTC QLQ and
PRO-CTCAE.

V. To compare clinician and patient reported toxicity using CTCAE and PRO CTCAE.

VI. To explore health utilities between cetuximab and MEDI4736 (durvalumab) RT using the
European Quality of Life 5 Dimensional-5 Level (EQ5D-5L).

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive cetuximab intravenously (IV) weekly over 60-120 minutes. Treatment
repeats every week for up to 8 cycles in the absence of disease progression or unacceptable
toxicity. Beginning 5-7 days after first cetuximab dose, patients undergo intensity modulated
radiation therapy (IMRT) 5 fractions per week for up to 7 weeks.

ARM II: Patients receive durvalumab IV over 60 minutes every 4 weeks. Treatment repeats every
4 weeks for up to 7 cycles in the absence of disease progression or unacceptable toxicity.
Beginning week 2, patients undergo IMRT 5 fractions per week for up to 7 weeks.

After completion of study treatment, patients are followed up at 1 month, every 4 months for
1 year, every 6 months for 2 years, then annually thereafter.

Inclusion Criteria:

- PRIOR TO STEP 1 REGISTRATION INCLUSION CRITERIA

- Patients must have pathologically confirmed, previously untreated, unresected squamous
cell carcinoma of the larynx, hypopharynx, oropharynx, oral cavity, or carcinoma of
unknown head/neck primary within 60 days prior to step 1 registration; submission of
hematoxylin and eosin (H&E) stained slides and formalin-fixed and paraffin-embedded
(FFPE) tissue block (or punch biopsy of FFPE block) to the biospecimen bank at
University of California, San Francisco (UCSF) for central review for oropharyngeal
and unknown primaries and for p16 analysis for all other non-oropharyngeal primaries
is mandatory for all patients; investigators should check with their pathology
department regarding release of biospecimens before approaching patients about
participation in the trial; for oropharyngeal and unknown primaries, submission of H&E
and p16 stained slides to the biospecimen bank at UCSF for central review is also
required prior to step 2 registration

- Note: fine needle aspirates (FNA) samples are not acceptable since they do not
provide enough material for PD-L1 and p16 testing

- Patients must have locoregionally advanced head and neck squamous cell carcinoma
(HNSCC)

- For p16-positive oropharyngeal/unknown primaries, American Joint Committee on
Cancer [AJCC] 8th edition stage III and selected stage I-II based on smoking
status in pack-years

- For laryngeal, hypopharyngeal, and oral cavity primaries and p16-negative
oropharyngeal/unknown primaries, AJCC 8th edition stage III-IVB

- Based on the following minimum diagnostic workup within 60 days prior to step 1
registration:

- General history and physical examination by a radiation oncologist or
medical oncologist or ear, nose and throat (ENT) or head & neck surgeon

- For larynx, hypopharynx, and base of tongue primaries, a
laryngopharyngoscopy (mirror and/or fiberoptic and/or direct procedure) is
required, unless the patient cannot tolerate or refuses

- Imaging of the head and neck with a neck CT or magnetic resonance imaging (MRI)
(with contrast, unless contraindicated) or PET/CT; note that the CT portion of
the PET/CT must be of diagnostic quality, including contrast administration
unless contraindicated. If the CT portion of the PET/CT study is low-dose
(non-diagnostic), then an additional CT or MRI study with contrast (unless
contraindicated) is required

- Chest imaging: chest CT with and without contrast (unless contraindicated) or
PET/CT

- Patients must have a contraindication to cisplatin as defined in the following bullet
points; sites must complete the online tool at comogram.org prior to step 1
registration to determine if the patient is eligible; the scores must be recorded on a
case report form (CRF)

- Age >= 70 with moderate to severe comorbidity or vulnerability to cisplatin,
defined as having any one or more of the following conditions within 30 days
prior to step 1 registration:

- Modified Charlson Comorbidity Index >= 1

- Adult Comorbidity Evaluation (ACE)-27 Index >= 1

- Generalized Competing Event Model for Cancer Risk (GCE) omega PFS score <
0.60

- Geriatric screening (G-8) score =< 14

- Cancer and Aging Research Group (CARG) toxicity score >= 30%

- Cumulative Illness Rating scale for Geriatrics (CIRS-G) score >= 4 OR

- Age < 70 with severe comorbidity or vulnerability to cisplatin, defined as having
two or more of the following conditions within 30 days prior to step 1
registration

- Modified Charlson Comorbidity Index >= 1

- ACE-27 Index >= 1

- GCE omega PFS-score < 0.60

- G-8 score =< 14

- CARG Toxicity score >= 30%

- CIRS-G score >= 4 OR

- Age >= 18 with an absolute or relative contraindication to cisplatin, defined as
one or more of the following within 30 days prior to step 1 registration:

- Creatinine clearance (CC) > 30 and < 60 cc/min; for this calculation, use
the Cockcroft-Gault formula

- Zubrod performance status 2 prior to step 1 registration

- Pre-existing peripheral neuropathy grade >= 1

- History of hearing loss, defined as either:

- Existing need of a hearing aid OR

- >= 25 decibel shift over 2 contiguous frequencies on a pretreatment
hearing test

- Absolute neutrophil count (ANC) >= 1,000 cells/mm^3 (within 14 days prior to step 1
registration)

- Platelets >= 100,000 cells/mm^3 (within 14 days prior to step 1 registration)

- Hemoglobin >= 9.0 g/dl (Note: the use of transfusion or other intervention to achieve
hemoglobin [Hgb] >= 9.0 g/dl is acceptable) (within 14 days prior to step 1
registration)

- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 times
institutional upper limit of normal (within 14 days prior to step 1 registration)

- Serum bilirubin =< 1.5 x institutional upper limit of normal (within 14 days prior to
step 1 registration)

- Measured creatinine clearance (CL) > 30 mL/min or calculated creatinine CL > 30 mL/min
by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine
collection for determination of creatinine clearance (within 14 days prior to step 1
registration)

- For women of childbearing potential, a negative serum or urine pregnancy test within
14 days prior to step 1 registration; Note: women will be considered post-menopausal
if they have been amenorrheic for 12 months without an alternative medical cause; the
following age-specific requirements apply:

- Women < 50 years of age would be considered post-menopausal if they have been
amenorrheic for 12 months or more following cessation of exogenous hormonal
treatments and if they have luteinizing hormone and follicle-stimulating hormone
levels in the post-menopausal range for the institution or underwent surgical
sterilization (bilateral oophorectomy or hysterectomy)

- Women >= 50 years of age would be considered post-menopausal if they have been
amenorrheic for 12 months or more following cessation of all exogenous hormonal
treatments, had radiation-induced menopause with last menses > 1 year ago, had
chemotherapy-induced menopause with last menses > 1 year ago, or underwent
surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or
hysterectomy)

- The patient or a legally authorized representative must provide study-specific
informed consent prior to step 1 registration

- PRIOR TO STEP 2 REGISTRATION INCLUSION CRITERIA

- For patients with oropharyngeal or unknown primaries: p16 determination by
immunohistochemistry (defined as greater than 70% strong nuclear or nuclear and
cytoplasmic staining of tumor cells), confirmed by central pathology review

- Note: for patients with oral cavity, laryngeal, and hypopharyngeal primaries,
analysis of p16 status prior to step 2 registration/randomization is not required
(p16 status will be analyzed centrally post-hoc); step 2 registration for these
patients can be completed after step 1 registration

Exclusion Criteria:

- PRIOR TO STEP 1 REGISTRATION EXCLUSION CRITERIA

- Prior invasive malignancy within the past 3 years (except for non-melanomatous skin
cancer, and early stage treated prostate cancer)

- Prior radiotherapy to the region of the study cancer that would result in overlap of
radiation therapy fields

- Prior immunotherapy

- Prior systemic therapy, including cytotoxic chemotherapy, biologic/targeted therapy,
or immune therapy for the study cancer

- Major surgery within 28 days prior to step 1 registration

- Proven evidence of distant metastases

- If both of the following conditions are present, the patient is ineligible:

- =< 10 pack-year smoking history

- p16-positive carcinoma of the oropharynx or unknown primary that are T0-3, N0-1
(AJCC 8th Edition)

- Note: in the event that a registered patient with =< 10 pack-years has a
p16-positive result on central review with the tumor and nodal stage T0-3,
N0-1 (AJCC 8th Edition), then the site will be notified that the patient is
ineligible

- Zubrod performance status >= 3

- Body weight =< 30 kg

- Patients with oral cavity cancer are excluded from participation if the patient is
medically operable and resection of the primary tumor is considered technically
feasible by an oral or head and neck cancers surgical subspecialist;(please consult
the surgical oncology co-principal investigator [PI], Steven Chang, Doctor of Medicine
[MD], if clarification is needed on an individual case)

- Sodium < 130 mmol/L or > 155 mmol/L (within 14 days of step 1 registration, unless
corrected prior to step 1 registration)

- Potassium < 3.5 mmol/L or > 6 mmol/L (within 14 days of step 1 registration, unless
corrected prior to step 1 registration)

- Fasting glucose < 40 mg/dl or > 400 mg/dl (within 14 days of step 1 registration,
unless corrected prior to step 1 registration)

- Serum calcium (ionized or adjusted for albumin) < 7 mg/dl or > 12.5 mg/dl (within 14
days of step 1 registration, unless corrected prior to step 1 registration)

- Magnesium < 0.9 mg/dl or > 3 mg/dl (within 14 days of step 1 registration, unless
corrected prior to step 1 registration)

- Unstable angina and/or congestive heart failure requiring hospitalization within 3
months prior to step 1 registration

- Transmural myocardial infarction within 3 months prior to step 1 registration

- Respiratory illness requiring hospitalization at the time of step 1 registration

- Note: if the respiratory illness is resolved and the patient meets the
eligibility status above, then the patient can be considered for the trial

- Idiopathic pulmonary fibrosis or other severe interstitial lung disease that requires
oxygen therapy or is thought to require oxygen therapy within 1 year prior to step 1
registration

- History of (non-infectious) pneumonitis that required steroids or current pneumonitis

- Clinically apparent jaundice and/or known coagulation defects

- Active or prior documented autoimmune or inflammatory disorders (including
inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with
the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome,
or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid
arthritis, hypophysitis, uveitis, etc.])

- The following are exceptions to this criterion:

- Patients with vitiligo or alopecia;

- Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on
hormone replacement;

- Any chronic skin condition that does not require systemic therapy;

- Patients without active disease in the last 5 years may be included but only
after consultation with the medical oncology study chair;

- Patients with celiac disease controlled by diet alone

- History of active primary immunodeficiency including, but not limited to acquired
immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and
Prevention (CDC) definition; Note: human immunodeficiency virus (HIV) testing is not
required for entry into this protocol; the need to exclude patients with AIDS from
this protocol is necessary because the treatment involved in this protocol may be
immunosuppressive; patients with known HIV, CD4 counts >= 200/uL, and undetectable
viral loads who are stable on an antiretroviral regimen may be included

- Current or prior use of immunosuppressive medication within 14 days before step 1
registration, with the exceptions of intranasal and inhaled corticosteroids or
systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of
prednisone, or an equivalent corticosteroid

- Receipt of live attenuated vaccination within 30 days prior to step 1 registration

- Medical or psychiatric illness which would compromise the patient's ability to
tolerate treatment or limit compliance with study requirements

- Pregnancy or women of childbearing potential and men who are sexually active and not
willing/able to use medically acceptable forms of contraception during treatment and
for 6 months after the last dose of cetuximab or MEDI14736 (durvalumab); this
exclusion is necessary because the treatment involved in this study may be
significantly teratogenic; women who are breastfeeding are also excluded

- Prior allergic reaction or hypersensitivity to cetuximab or MEDI4736 (durvalumab) or
any of study drug excipients

- History of allogenic organ transplantation

- Uncontrolled hypertension

- Uncontrolled cardiac arrhythmia

- Uncontrolled serious chronic gastrointestinal condition associated with diarrhea

- Active infection including tuberculosis (clinical evaluation that includes clinical
history, physical examination and radiographic findings, and tuberculosis [TB] testing
in line with local practice), hepatitis B (known positive hepatitis B virus [HBV]
surface antigen [HBsAg] result), hepatitis C; patients with a past or resolved HBV
infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence
of HBsAg) are eligible; patients positive for hepatitis C (hepatitis C virus [HCV])
antibody are eligible only if polymerase chain reaction is negative for HCV
ribonucleic acid (RNA)
We found this trial at
93
sites
Lewisburg, Pennsylvania 17837
Principal Investigator: Anand Mahadevan
Phone: 570-374-8555
?
mi
from
Lewisburg, PA
Click here to add this to my saved trials
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
(505) 272-4946
Principal Investigator: Gregory N. Gan
Phone: 505-925-0366
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Principal Investigator: Anurag K. Singh
Phone: 800-767-9355
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
1500 E Duarte Rd
Duarte, California 91010
(626) 256-4673
Principal Investigator: Sagus Sampath
Phone: 800-826-4673
City of Hope Comprehensive Cancer Center City of Hope is a leading research and treatment...
?
mi
from
Duarte, CA
Click here to add this to my saved trials
401 College Street
Richmond, Virginia 23298
(804) 828-0450
Principal Investigator: Sarah W. Gordon
Virginia Commonwealth University Massey Cancer Center Founded in 1974, VCU Massey Cancer Center is a...
?
mi
from
Richmond, VA
Click here to add this to my saved trials
1200 Old York Road
Abington, Pennsylvania 19001
(215) 481–2000
Principal Investigator: Willard G. Andrews
Phone: 215-481-2402
Abington Memorial Hospital Abington Memorial Hospital (AMH) is a 665-bed, regional referral center and teaching...
?
mi
from
Abington, PA
Click here to add this to my saved trials
Albuquerque, New Mexico 87109
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
800-865-1125
Principal Investigator: Francis P. Worden
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Antigo, Wisconsin 54409
Principal Investigator: Christopher S. Platta
Phone: 715-623-9869
?
mi
from
Antigo, WI
Click here to add this to my saved trials
Atlanta, Georgia 30322
Principal Investigator: Jonathan J. Beitler
Phone: 404-778-1868
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
550 Peachtree St NE
Atlanta, Georgia 30308
(404) 686-4411
Principal Investigator: Jonathan J. Beitler
Phone: 888-946-7447
Emory University Hospital Midtown Emory University Hospital Midtown is a 511-bed community-based, acute care teaching...
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
12605 East 16th Avenue
Aurora, Colorado 80045
720-848-0000
Principal Investigator: Sana D. Karam
Phone: 720-848-0650
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
Bemidji, Minnesota 56601
Principal Investigator: Preston D. Steen
Phone: 218-333-5000
?
mi
from
Bemidji, MN
Click here to add this to my saved trials
Boston, Massachusetts 02118
Principal Investigator: Minh T. Truong
Phone: 617-638-8265
?
mi
from
Boston, MA
Click here to add this to my saved trials
Bronx, New York 10467
Principal Investigator: Rafi Kabarriti
Phone: 718-379-6862
?
mi
from
Bronx, NY
Click here to add this to my saved trials
Brownstown, Michigan 48183
Principal Investigator: Eleanor M. Walker
Phone: 313-916-3721
?
mi
from
Brownstown, MI
Click here to add this to my saved trials
Burlington, Massachusetts 01805
Principal Investigator: Francis W. Nugent
Phone: 781-744-8027
?
mi
from
Burlington, MA
Click here to add this to my saved trials
171 Ashley Avenue
Charleston, South Carolina 29425
843-792-1414
Principal Investigator: Anand K. Sharma
Phone: 843-792-9321
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
?
mi
from
Charleston, SC
Click here to add this to my saved trials
Charlotte, North Carolina 28204
Principal Investigator: Daniel R. Carrizosa
Phone: 800-804-9376
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Principal Investigator: Victoria M. Villaflor
Phone: 312-695-1301
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Cincinnati, Ohio 45219
Principal Investigator: Jordan Kharofa
Phone: 513-558-4553
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
5680 Bow Pointe Drive
Clarkston, Michigan 48346
Principal Investigator: Kiran Devisetty
Phone: 313-576-9790
?
mi
from
Clarkston, MI
Click here to add this to my saved trials
10900 Euclid Ave
Cleveland, Ohio 44106
216-368-2000
Principal Investigator: Min Yao
Phone: 800-641-2422
Case Western Reserve Univ Continually ranked among America's best colleges, Case Western Reserve University has...
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
Clinton Township, Michigan 48038
Principal Investigator: Eleanor M. Walker
Phone: 313-916-3721
?
mi
from
Clinton Township, MI
Click here to add this to my saved trials
6001 E Woodmen Rd
Colorado Springs, Colorado 80923
(719) 776-5000
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Penrose-Saint Francis Healthcare Founded by the Sisters of St. Francis and the Sisters of Charity,...
?
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: Marcelo R. Bonomi
Phone: 800-293-5066
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Concord, North Carolina 28025
Principal Investigator: Daniel R. Carrizosa
Phone: 704-403-1520
?
mi
from
Concord, NC
Click here to add this to my saved trials
Corvallis, Oregon 97330
Principal Investigator: David M. Hufnagel
Phone: 541-768-4352
?
mi
from
Corvallis, OR
Click here to add this to my saved trials
10 Barnes West Drive
Creve Coeur, Missouri 63141
Principal Investigator: Douglas R. Adkins
Phone: 800-600-3606
?
mi
from
Creve Coeur, MO
Click here to add this to my saved trials
100 North Academy Avenue
Danville, Pennsylvania 17822
570-271-6211
Principal Investigator: Anand Mahadevan
Phone: 570-271-5251
Geisinger Medical Center Since 1915, Geisinger Medical Center has been known as the region’s resource...
?
mi
from
Danville, PA
Click here to add this to my saved trials
2300 N Edward St
Decatur, Illinois 62526
(217) 876-8121
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
Decatur Memorial Hospital An American flag bearing only 48 stars waved above Decatur Memorial Hospital...
?
mi
from
Decatur, IL
Click here to add this to my saved trials
1200 Pleasant St
Des Moines, Iowa 50309
(515) 241-6212
Principal Investigator: Robert J. Behrens
Phone: 515-241-6727
Iowa Methodist Medical Center Iowa Methodist Medical Center was established in 1901 in a single...
?
mi
from
Des Moines, IA
Click here to add this to my saved trials
2799 W Grand Blvd
Detroit, Michigan 48202
(313) 916-2600
Principal Investigator: Eleanor M. Walker
Phone: 313-916-3721
Henry Ford Hospital Founded in 1915 by auto pioneer Henry Ford and now one of...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
4160 John R St #2122
Detroit, Michigan 48201
(313) 833-1785
Principal Investigator: Kiran Devisetty
Phone: 313-576-9790
Wayne State University/Karmanos Cancer Institute Karmanos is based in southeast Michigan, in midtown Detroit, and...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Effingham, Illinois 62401
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
?
mi
from
Effingham, IL
Click here to add this to my saved trials
Fargo, North Dakota 58122
Principal Investigator: Preston D. Steen
Phone: 701-234-6161
?
mi
from
Fargo, ND
Click here to add this to my saved trials
Flint, Michigan 48532
Principal Investigator: Kiran Devisetty
Phone: 313-576-9790
?
mi
from
Flint, MI
Click here to add this to my saved trials
1024 S Lemay Ave
Fort Collins, Colorado 80524
(970) 495-7000
Principal Investigator: Sana D. Karam
Phone: 970-297-6150
Poudre Valley Hospital A 270-bed regional medical center offering a wide array of treatments, surgeries,...
?
mi
from
Fort Collins, CO
Click here to add this to my saved trials
2200 Randallia Drive
Fort Wayne, Indiana 46805
Principal Investigator: Sarah Y. Wang
Phone: 260-373-8888
?
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Fort Wayne, Indiana 46845
Principal Investigator: Sarah Y. Wang
Phone: 877-784-4673
?
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Grand Island, Nebraska 68803
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Grand Island, NE
Click here to add this to my saved trials
Greer, South Carolina 29651
Principal Investigator: Abderrahim Khomani
Phone: 864-560-6104
?
mi
from
Greer, SC
Click here to add this to my saved trials
Hendersonville, North Carolina 28791
Principal Investigator: James E. Radford
Phone: 828-696-4716
?
mi
from
Hendersonville, NC
Click here to add this to my saved trials
Honolulu, Hawaii 96817
Principal Investigator: Richard Y. Lee
Phone: 808-547-6881
?
mi
from
Honolulu, HI
Click here to add this to my saved trials
1301 Punchbowl St
Honolulu, Hawaii 96813
(808) 538-9011
Principal Investigator: Richard Y. Lee
Phone: 412-339-5294
Queen's Medical Center The Queen's Medical Center, located in downtown Honolulu, Hawaii, is a private,...
?
mi
from
Honolulu, HI
Click here to add this to my saved trials
1400 North Ritter Avenue
Indianapolis, Indiana 46219
Principal Investigator: Shih J. Wei
Phone: 800-777-7775
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Indianapolis, Indiana 46256
Principal Investigator: Shih J. Wei
Phone: 317-621-7104
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Indianapolis, Indiana 46227
Principal Investigator: Shih J. Wei
Phone: 317-497-2823
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Jacksonville, Florida 32207
Principal Investigator: Anterpreet S. Neki
Phone: 904-202-7051
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
310 Sunnyview Ln
Kalispell, Montana 59901
(406) 752-5111
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Kalispell Regional Medical Center Nestled in the beautiful Flathead Valley of Northwestern Montana, Kalispell Regional...
?
mi
from
Kalispell, MT
Click here to add this to my saved trials
La Crosse, Wisconsin
Principal Investigator: Collin D. Driscoll
Phone: 608-775-2385
?
mi
from
La Crosse, WI
Click here to add this to my saved trials
Lansing, Michigan 48910
Principal Investigator: Kiran Devisetty
Phone: 313-576-9790
?
mi
from
Lansing, MI
Click here to add this to my saved trials
Lapeer, Michigan 48446
Principal Investigator: Kiran Devisetty
Phone: 313-576-9790
?
mi
from
Lapeer, MI
Click here to add this to my saved trials
Lexington, Kentucky
Principal Investigator: Susanne M. Arnold
Phone: 859-257-3379
?
mi
from
Lexington, KY
Click here to add this to my saved trials
Louisville, Kentucky 40202
Principal Investigator: Neal E. Dunlap
Phone: 502-562-3429
?
mi
from
Louisville, KY
Click here to add this to my saved trials
2000 N Boise Ave
Loveland, Colorado 80538
(970) 669-4640
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
McKee Medical Center Through the years, McKee has led the way in health care innovation....
?
mi
from
Loveland, CO
Click here to add this to my saved trials
Menomonee Falls, Wisconsin 53051
Principal Investigator: Stuart J. Wong
Phone: 262-257-5100
?
mi
from
Menomonee Falls, WI
Click here to add this to my saved trials
9200 W Wisconsin Ave
Milwaukee, Wisconsin 53226
(414) 805-3666
Principal Investigator: Stuart J. Wong
Phone: 414-805-4380
Froedtert and the Medical College of Wisconsin Froedtert Health combines with the Medical College of...
?
mi
from
Milwaukee, WI
Click here to add this to my saved trials
1660 Springhill Avenue
Mobile, Alabama 36604
(251) 665-8000
Principal Investigator: Sachin G. Pai
Phone: 251-445-9870
University of South Alabama Mitchell Cancer Institute USA Mitchell Cancer Institute (MCI) is located in...
?
mi
from
Mobile, AL
Click here to add this to my saved trials
Monroe, North Carolina 28112
Principal Investigator: Daniel R. Carrizosa
Phone: 412-339-5294
?
mi
from
Monroe, NC
Click here to add this to my saved trials
Mount Clemens, Michigan 48043
Principal Investigator: Kiran Devisetty
Phone: 313-576-9790
?
mi
from
Mount Clemens, MI
Click here to add this to my saved trials
New York, New York 10032
Principal Investigator: Matthen Mathew
Phone: 212-305-6361
?
mi
from
New York, NY
Click here to add this to my saved trials
Newark, Delaware 19713
Principal Investigator: Gregory A. Masters
Phone: 302-623-4450
?
mi
from
Newark, DE
Click here to add this to my saved trials
600 Gresham Dr
Norfolk, Virginia 23507
(757) 388-3000
Principal Investigator: Edwin F. Crandley
Phone: 757-388-2406
Sentara Norfolk General Hospital Sentara Norfolk General Hospital is recognized as the number one ranked...
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
940 NE 13th St
Oklahoma City, Oklahoma 73190
(405) 271-6458
Principal Investigator: J. S. Thompson
Phone: 405-271-8777
University of Oklahoma Health Sciences Center The OU Health Sciences Center is composed of seven...
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
875 Blake Wilbur Drive
Palo Alto, California 94304
Principal Investigator: Beth M. Beadle
Phone: 650-498-7061
?
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Peoria, Illinois 61637
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
?
mi
from
Peoria, IL
Click here to add this to my saved trials
Petoskey, Michigan 49770
Principal Investigator: Kiran Devisetty
Phone: 313-576-9790
?
mi
from
Petoskey, MI
Click here to add this to my saved trials
1221 Pine Grove Avenue
Port Huron, Michigan 48060
Principal Investigator: Kiran Devisetty
Phone: 313-576-9790
?
mi
from
Port Huron, MI
Click here to add this to my saved trials
Portland, Oregon 97227
Principal Investigator: Sandeep H. Mashru
Phone: 503-335-2400
?
mi
from
Portland, OR
Click here to add this to my saved trials
Rochester, Minnesota 55905
Principal Investigator: Helen J. Ross
Phone: 855-776-0015
?
mi
from
Rochester, MN
Click here to add this to my saved trials
Sacramento, California 95819
Principal Investigator: Christopher U. Jones
Phone: 916-454-6500
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
Saint Johnsbury, Vermont 05819
Principal Investigator: Philip E. Schaner
Phone: 802-473-4100
?
mi
from
Saint Johnsbury, VT
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Principal Investigator: Douglas R. Adkins
Phone: 800-600-3606
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
150 Entranceway Drive
Saint Peters, Missouri 63376
Principal Investigator: Douglas R. Adkins
Phone: 800-600-3606
?
mi
from
Saint Peters, MO
Click here to add this to my saved trials
San Francisco, California 94115
Principal Investigator: Sue S. Yom
Phone: 877-827-3222
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
Sayre, Pennsylvania 18840
Principal Investigator: Philip A. Lowry
Phone: 800-836-0388
?
mi
from
Sayre, PA
Click here to add this to my saved trials
1305 W 18th St
Sioux Falls, South Dakota 57117
(605) 333-1000
Principal Investigator: Preston D. Steen
Phone: 605-312-3320
Sanford USD Medical Center - Sioux Falls Sanford
?
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Spartanburg, South Carolina 29303
Principal Investigator: Abderrahim Khomani
Phone: 864-560-6104
?
mi
from
Spartanburg, SC
Click here to add this to my saved trials
701 N 1st St
Springfield, Illinois 62781
(217) 788-3000
Principal Investigator: Bryan A. Faller
Phone: 217-788-3528
Memorial Medical Center Memorial Medical Center is a Magnet-designated, acute care hospital in Springfield that...
?
mi
from
Springfield, IL
Click here to add this to my saved trials
Tampa, Florida 33612
Principal Investigator: Julie A. Kish
Phone: 800-456-7121
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Tucson, Arizona 85724
Principal Investigator: Julie E. Bauman
Phone: 520-626-9008
?
mi
from
Tucson, AZ
Click here to add this to my saved trials
Tucson, Arizona 85719
Principal Investigator: Julie E. Bauman
Phone: 800-327-2873
?
mi
from
Tucson, AZ
Click here to add this to my saved trials
602 W University Ave
Urbana, Illinois 61801
(217) 383-3010
Principal Investigator: Yujie Zhao
Phone: 800-446-5532
Carle Cancer Center Carle Cancer Center delivers comprehensive care through leading-edge technology and advanced research,...
?
mi
from
Urbana, IL
Click here to add this to my saved trials
Waukesha, Wisconsin 53188
Principal Investigator: Timothy R. Wassenaar
Phone: 262-928-5539
?
mi
from
Waukesha, WI
Click here to add this to my saved trials
Wausau, Wisconsin 54401
Principal Investigator: Christopher S. Platta
Phone: 877-405-6866
?
mi
from
Wausau, WI
Click here to add this to my saved trials
West Bend, Wisconsin 53095
Principal Investigator: Stuart J. Wong
Phone: 866-680-0505
?
mi
from
West Bend, WI
Click here to add this to my saved trials
West Bloomfield, Michigan 48322
Principal Investigator: Eleanor M. Walker
Phone: 313-916-3721
?
mi
from
West Bloomfield, MI
Click here to add this to my saved trials
West Chester, Ohio 45069
Principal Investigator: Jordan Kharofa
?
mi
from
West Chester, OH
Click here to add this to my saved trials
300 South 6th Avenue
West Reading, Pennsylvania 19611
(610) 988-8000
Principal Investigator: Terrence P. Cescon
Phone: 610-988-9323
Reading Hospital At Reading Health System, advancing your health and wellness is our mission. When...
?
mi
from
West Reading, PA
Click here to add this to my saved trials
929 N St Francis St
Wichita, Kansas 67214
(316) 268-5775
Principal Investigator: Pavan S. Reddy
Phone: 800-362-0070
Via Christi Regional Medical Center Via Christi Health's rich history of serving the people of...
?
mi
from
Wichita, KS
Click here to add this to my saved trials
Wilkes-Barre, Pennsylvania 18711
Principal Investigator: Anand Mahadevan
Phone: 570-271-5251
?
mi
from
Wilkes-Barre, PA
Click here to add this to my saved trials
3941 Commerce Avenue
Willow Grove, Pennsylvania 19090
Principal Investigator: Willard G. Andrews
Phone: 215-481-2402
?
mi
from
Willow Grove, PA
Click here to add this to my saved trials